Furthermore, a phase Ib clinical trial is evaluating the combination of niraparib and copanlisib, a PI3K inhibitor, in BRCA1/2-mutated ovarian, endometrial, or fallopian tube cancer (NCT03586661). Here, BRCA1 is linked to fallopian tube cancer.